Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic administration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting data from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical trials in this subset of patients.
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? / Cazzaniga, M.E., Cortesi, L., Ferzi, A., Scaltriti, L., Cicchiello, F., Ciccarese, M., Torre, S.D., Villa, F., Giordano, M., Verusio, C., Nicolini, M., Gambaro, A.R., Zanlorenzi, L., Biraghi, E., Casini, E., Legramandi, L., Rulli, E.. - In: INTERNATIONAL JOURNAL OF BREAST CANCER. - ISSN 2090-3189. - 2017:(2017), pp. N/A-N/A. [10.1155/2017/1683060]
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
Cortesi L.;
2017
Abstract
Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease. Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic administration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting data from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical trials in this subset of patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
International Journal of Breast Cancer - 2017 - Cazzaniga - Metronomic Chemotherapy in Triple‐Negative Metastatic Breast.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
369.51 kB
Formato
Adobe PDF
|
369.51 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
